Advantages |
Faster accrual from more sites for patients with common cancers and with all stages of disease |
Faster accrual for patients with uncommon and rare tumors, specific molecular defects, and less common histologic subtypes |
Broader applicability of research results |
Fewer duplicative trials |
More complementary trials |
More rapid dissemination of innovations in cancer treatment |
Disadvantages |
Differing regulations between countries |
Differing levels of infrastructure support for cancer clinical trials between countries |
Differing processes and schedules for scientific review by funding bodies between countries |
Longer lead time for concept and trial development |
Differing licensing arrangements for specific drugs between countries |
Contractual issues with pharmaceutical companies in different countries |
Drug distribution issues in different countries |